Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ325M)

Drug Name

CGP-53716 Drug Info

Synonyms

CGS-53716

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Platelet-derived growth factor receptor (PDGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[4]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[5]
CT-102	DMB8PF3	Diabetic foot ulcer	BD54	Approved	[6]
Trapidil	DMY67U8	Acute coronary syndrome	BA41	Phase 4	[7]
TKI258	DMYLT67	Renal cell carcinoma	2C90	Phase 3	[3]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[3]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[8]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[9]
PMID25623274-Compound-WO2014132220C2	DMXEZWP	Pulmonary arterial hypertension	BB01.0	Patented	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005535)
2	Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther. 1997 Oct;283(1):402-10.
3	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
7	Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
8	National Cancer Institute Drug Dictionary (drug id 695817).
9	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
10	Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9.